New test to better predict breast cancer outcomes discovered
January 28th, 2011 - 5:41 pm ICT by ANIWashington, Jan 28 (ANI): Scientists have discovered a gene signature that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not from the burdens associated with unnecessary treatment.
The discovery was made by researchers from McGill University’s Rosalind and Morris Goodman Cancer Research Centre (GCRC), the Research Institute of the McGill University Health Centre (RI MUHC), the Dana-Farber Cancer Institute and Harvard Medical School.
For years, clinicians have been faced with the problem that breast cancer cannot be treated with a one-size-fits-all approach.
Some cancers respond to specific treatments while others do not. Close to 50 per cent of breast cancer patients belong to a group - defined as “estrogen receptor positive/lymph node negative (ER+/LR-)”- that is at low risk of relapse.
The majority of patients in this group may not require any treatment beyond the surgical removal of their tumour, while a small minority should receive additional treatment.
“The added information provided by our test would enable oncologists to identify those at very low risk of relapse, for whom the risk-benefit ratio might be in favour of withholding chemotherapy, and to identify patients in this low-risk group who would benefit from more aggressive treatments,” explains Dr. Alain Nepveu, GCRC and RI MUHC researcher and co-author of the study.
“Since many treatments are associated with short- and long-term complications including premature menopause, cardiotoxicity and the development of secondary cancers, risks must be balanced against the potential benefit for each patient to avoid unnecessary suffering, needless expense and added burdens on the health-care system.”
While more research is required before the test would be ready for market and incorporated into existing diagnostic procedures, Nepveu suggests it has the potential to be commercialized within five years.
These findings were published in a recent issue the Proceedings of the National Academy of Sciences. (ANI)
- Exposure to low-dose radiation 'ups cancer risk' - Feb 08, 2011
- Breast cancer linked to traffic-related air pollution - Oct 07, 2010
- Study solves 35-yr-old medical mystery using genetics - Jan 29, 2011
- Circulating tumour cells in blood up death risk in early-stage breast cancer patients - Dec 11, 2010
- WHO should revise TB treatment guidelines, say scientists - Sep 15, 2009
- Genetic pathways involved in breast cancer identified - Mar 04, 2011
- Breast cancer survivors who set new goals are healthier - Apr 24, 2012
- New 'Nanobody' agents help identify patients who will benefit from breast cancer drugs - Apr 12, 2011
- Worrying about breast cancer returning can hit women's quality of life - Mar 28, 2011
- Relief from chronic back pain normalises brain activity - May 18, 2011
- Childhood cancer may be linked to later heart problems - Jul 27, 2010
- Vitamin D deficiency leads to obesity, stunts growth - Mar 08, 2010
- Cheap diabetes drug could help fight breast cancer - Apr 15, 2011
- Inflammatory diseases linked to increased cardiovascular risk - Sep 02, 2009
- Chemotherapy post-surgery 'may not be always necessary' - Nov 09, 2010
Tags: aggressive treatments, benefit ratio, breast cancer, breast cancer outcomes, breast cancer patients, cancer research centre, cardiotoxicity, dana farber cancer, dana farber cancer institute, farber cancer institute, gcrc, harvard medical school, mcgill university health, mcgill university health centre, morris goodman, muhc, needless expense, secondary cancers, university health centre, unnecessary treatment